title: Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging.
abstract: Xenograft tumor models are widely studied in cancer research. Our aim was to establish and apply a model for aggressive CD20-positive B-cell non-Hodgkin lymphomas, enabling us to monitor tumor growth and shrinkage in a noninvasive manner. By stably transfecting a luciferase expression vector, we created two bioluminescent human non-Hodgkin lymphoma cell lines, Jeko1(luci) and OCI-Ly3(luci), that are CD20 positive, a prerequisite to studying rituximab, a chimeric anti-CD20 antibody. To investigate the therapy response in vivo, we established a disseminated xenograft tumor model injecting these cell lines in NOD/SCID mice. We observed a close correlation of bioluminescence intensity and tumor burden, allowing us to monitor therapy response in the living animal. Cyclophosphamide reduced tumor burden in mice injected with either cell line in a dose-dependent manner. Rituximab alone was effective in OCI-Ly3(luci)-injected mice and acted additively in combination with cyclophosphamide. In contrast, it improved the therapeutic outcome of Jeko1(luci)-injected mice only in combination with cyclophosphamide. We conclude that well-established bioluminescence imaging is a valuable tool in disseminated xenograft tumor models. Our model can be translated to other cell lines and used to examine new therapeutic agents and schedules.
authors.forename: Margarethe
authors.initials: M
authors.lastname: Köberle
authors.forename: Kristin
authors.initials: K
authors.lastname: Müller
authors.forename: Manja
authors.initials: M
authors.lastname: Kamprad
authors.forename: Friedemann
authors.initials: F
authors.lastname: Horn
authors.forename: Markus
authors.initials: M
authors.lastname: Scholz
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D002452:Cell Count; D045744:Cell Line, Tumor; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D008156:Luciferases / Q000378:metabolism; D008163:Luminescent Measurements / Q000379:methods*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D009928:Organ Specificity / Q000187:drug effects; D000069283:Rituximab / Q000494:pharmacology / Q000627:therapeutic use; D014162:Transfection; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor; D000069283:Rituximab; D003520:Cyclophosphamide; D008156:Luciferases